JP2024532503A5 - - Google Patents
Info
- Publication number
- JP2024532503A5 JP2024532503A5 JP2024514046A JP2024514046A JP2024532503A5 JP 2024532503 A5 JP2024532503 A5 JP 2024532503A5 JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024532503 A5 JP2024532503 A5 JP 2024532503A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- target polypeptide
- terminus
- fusion protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111026970.5 | 2021-09-02 | ||
| CN202111026970 | 2021-09-02 | ||
| PCT/CN2022/116513 WO2023030444A1 (zh) | 2021-09-02 | 2022-09-01 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532503A JP2024532503A (ja) | 2024-09-05 |
| JP2024532503A5 true JP2024532503A5 (https=) | 2025-08-14 |
Family
ID=85411955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514046A Pending JP2024532503A (ja) | 2021-09-02 | 2022-09-01 | Ｇｌｐ－１／ｇｉｐデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250223331A1 (https=) |
| EP (1) | EP4410827A4 (https=) |
| JP (1) | JP2024532503A (https=) |
| CN (1) | CN115850437A (https=) |
| WO (1) | WO2023030444A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| US12281149B2 (en) | 2021-05-13 | 2025-04-22 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| WO2025049610A1 (en) * | 2023-08-28 | 2025-03-06 | Shattuck Labs, Inc. | Multi-action peptides |
| US20250270274A1 (en) * | 2024-02-26 | 2025-08-28 | Serpentide Inc. | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity |
| CN120829494A (zh) * | 2024-04-18 | 2025-10-24 | 苏州星曜坤泽生物制药有限公司 | 一种glp-1gip类似物、fgf21蛋白、三功能蛋白及其应用 |
| WO2026046352A1 (zh) * | 2024-08-30 | 2026-03-05 | 石药集团巨石生物制药有限公司 | 一种gip/glp-1受体共激动剂及其应用 |
| CN118955739B (zh) * | 2024-10-17 | 2025-02-18 | 华南理工大学 | 一种双靶点受体激动剂融合蛋白及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102105159B (zh) * | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| US20130090285A1 (en) * | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| IN2014MN02304A (https=) * | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| HK1209034A1 (en) * | 2012-06-21 | 2016-03-24 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| WO2015067715A2 (en) * | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| WO2016131893A1 (en) * | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| CN111111264A (zh) * | 2019-12-31 | 2020-05-08 | 杭州九源基因工程有限公司 | 制备多肽步骤中色谱固定相的再生方法 |
-
2022
- 2022-09-01 US US18/688,258 patent/US20250223331A1/en active Pending
- 2022-09-01 JP JP2024514046A patent/JP2024532503A/ja active Pending
- 2022-09-01 WO PCT/CN2022/116513 patent/WO2023030444A1/zh not_active Ceased
- 2022-09-01 CN CN202211067063.XA patent/CN115850437A/zh active Pending
- 2022-09-01 EP EP22863579.3A patent/EP4410827A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532503A5 (https=) | ||
| JP7461438B2 (ja) | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 | |
| US9260496B2 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| ES2328510T3 (es) | Proteinas de fusion glp-1. | |
| Chen et al. | Fusion protein linkers: property, design and functionality | |
| ES2842677T3 (es) | Ligandos modificados mediante permutación circular como agonistas y antagonistas | |
| JP2011501959A5 (https=) | ||
| JP2018171063A5 (https=) | ||
| HRP20250309T1 (hr) | Proteini s dvostrukom funkcijom i farmaceutski pripravak koji ih sadrži | |
| JP2023518596A5 (https=) | ||
| AU2017273743B2 (en) | Serum albumin-binding fibronectin type III domains | |
| JP2012505902A5 (https=) | ||
| JP2018515088A5 (https=) | ||
| JP2005514060A5 (https=) | ||
| JP2005528337A5 (https=) | ||
| JP2023505492A5 (https=) | ||
| JP2020517260A5 (https=) | ||
| JP2025512865A5 (https=) | ||
| JP2022522787A5 (https=) | ||
| JP2023524981A5 (https=) | ||
| WO2023143563A1 (zh) | IgA蛋白酶截短体、包含IgA蛋白酶截短体的融合蛋白及其用途 | |
| JP2008528004A5 (https=) | ||
| CN111234015B (zh) | 用于延长药物半衰期的抗体、其融合蛋白和应用 | |
| RU2369404C2 (ru) | Слитые белки альбумина | |
| CN103601808B (zh) | 钠肽、制备方法及其在制备基因工程药物中的应用 |